source
- STAT+: FDA revisits a rare cancer treatment it rejected a few months agoSecret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The ReadoutSTAT · 2mo ago↗ source
- Atara, Pierre Fabre's cell therapy to get another shot at FDA approvalThere's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an a…Endpoints · 2mo ago↗ source
- STAT+: OpenAI’s health policy wishlist, CGM news from Dexcom, and moreIn this edition of STAT Health Tech: A health policy blueprint from OpenAI, CGM updates from Dexcom, and push back against whole body scans.STAT · 2mo ago